The Coding and Non-Coding Genomic Landscape of Hepatocellular Carcinoma: Etiological Risk Factors and their Current Clinical Implications.

Authors

Ana Maria Ciurdorean, Paul Chiroi, Daniel Gabriel Cosma, Mihai Dumitru Porojan, Ioana Rusu, Stefan Strilciuc, Ioana Berindan-Neagoe, Nadim Al Hajjar

Published in

Journal of gastrointestinal and liver diseases : JGLD. Volume 35. Issue 3. Pages 455-468. Sep 26, 2026. Epub Sep 26, 2026.

Abstract

Hepatocellular carcinoma (HCC) is the most common liver malignancy and a leading cause of cancer mortality, with burden projected to rise substantially by 2040. Its poor prognosis reflects the timing of diagnosis: HCC develops silently against chronic liver disease, and six-monthly ultrasound with alpha-fetoprotein remains insensitive in the early stages. Two developments have reshaped molecular understanding of this heterogeneous cancer. Large-scale sequencing established that the somatic landscape is not etiology-agnostic. The driver hierarchy is dominated by TERT, TP53, and CTNNB1; exposure-specific mutational signatures; and structural events such as hepatitis B virus integration, all of which differ systematically by upstream cause. In parallel, a dense non-coding regulatory layer has been shown to intersect with the core processes of hepatocarcinogenesis. These layers have largely been reviewed in isolation. Here, we integrate them, organize the coding and non-coding genomic architecture of HCC by etiological risk factor, and appraise the contributions of each to clinical decision-making. Etiological patterning is asymmetric - well-established at the coding layer but not yet demonstrated at the non-coding layer, where assignments derive from single-etiology cohorts compared across studies, platforms, and normalization strategies. Cutting across both layers are convergent nodes shared by all causes, most clearly depletion of the hepatoprotective microRNA-122, a marker of convergence rather than specificity. We then assess the clinical interface: multi-analyte serum scores and methylation-based cell-free DNA now outperform ultrasound for early detection in prospective cohorts, yet none is guideline-endorsed, and no circulating non-coding RNA has reached prospective validation. The near-term clinical yield of this field lies in risk stratification, not molecularly guided therapy.

PMID:
42803249
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.